๐Ÿ”ฌ Third-party verified peptides ยท Free Express Post over $200 CAD
Pantheon Peptides
Muscle Growth3 cited studies

CJC-1295 (no DAC)

GHRH analog that stimulates pulsatile growth hormone secretion (no DAC).

Also known as: CJC-1295 ยท CJC 1295 ยท CJC1295
SummaryMechanismDosingSafetyStudies
Research use only โ€” not for human consumption.

What it is

CJC-1295 (without DAC) is a modified Growth Hormone Releasing Hormone (GHRH) analog that stimulates the pituitary gland to produce and release growth hormone while preserving natural pulsatile release patterns. Popular in fitness and wellness contexts for lean muscle growth, recovery, and improved sleep quality, with anti-aging effects on cellular repair, skin elasticity, and bone health. This product does NOT include DAC (Drug Affinity Complex).

Mechanism of action

Binds GHRH receptors on anterior pituitary somatotrophs, triggering GH release. Modifications at positions 2, 8, 15, and 27 protect against DPP-IV enzymatic degradation, extending activity versus native GHRH.

Half-life: ~30 minutes (without DAC).

Evidence summary

Phase 1/2 trials demonstrated dose-dependent increases in GH and IGF-1 over 28 days. Most published clinical work used the CJC-1295 with DAC variant; the no-DAC form preserves pulsatile release.

Typical dosing protocols

Typical dose
100โ€“200 mcg
Frequency
Once daily
Cycle length
12 weeks
  • 100โ€“200 mcg subcutaneous before bed, once daily
  • Often paired with Ipamorelin for synergistic GH release
  • 12-week cycles with at least 4 weeks off between

Side effects & safety

  • Injection-site flushing or redness
  • Headache, lightheadedness (uncommon)
  • Water retention at higher doses

Cited studies

  1. Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism.
    PMID 16352683Read source โ†—
  2. Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism.
    PMID 16940451Read source โ†—
  3. (2007). A Study to Evaluate CJC-1295 in HIV-Associated Visceral Obesity. ClinicalTrials.gov (NCT00267527).
    Read source โ†—
Disclaimer

All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.